Adagene

company

About

Adagene is a clinical-stage biotech company that specializes in developing immuno-oncology antibodies.

  • 51 - 100

Details

Last Funding Type
Series C
Last Funding Money Raised
$50M
Industries
Biotechnology,Medical,Therapeutics
Founded date
Jan 1, 2011
Number Of Employee
51 - 100
Operating Status
Active

Adagene is a clinical-stage biotech company that specializes in developing immuno-oncology antibodies against novel epitopes. It has its proprietary Smart Antibody Technology, which increases success rates, substantially accelerates time to market, and reduces the costs associated with developing a therapeutic antibody.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$50M
Adagene has raised a total of $50M in funding over 2 rounds. Their latest funding was raised on Mar 27, 2018 from a Series C round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 27, 2018 Series C $50M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Adagene is funded by 1 investors. King Star Capital are the most recent investors.
Investor Name Lead Investor Funding Round
King Star Capital Series C